XOMA Ltd. announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and congestive heart failure.
CNNMoney